{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":"metastatic castration-resistant prostate cancer","name":"NCT03089203","nct_id":"NCT03089203","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03089203. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"CART-PSMA-TGFβRDN cells 1-3x10\\^7 Day 0","label":"Cohort 1","type":"EXPERIMENTAL"},{"description":"CART-PSMA-TGFβRDN cells 1-3x10\\^8 Day 0","label":"Cohort 2","type":"EXPERIMENTAL"},{"description":"CART-PSMA-TGFβRDN cells 1-3x10\\^7 Day 0","label":"Cohort -3","type":"EXPERIMENTAL"},{"description":"CART-PSMA-TGFβRDN cells 0.70-1.00 x 10\\^8 Day 0","label":"Cohort 4","type":"EXPERIMENTAL"},{"description":"CART-PSMA-TGFβRDN cells at the MTD (established by Cohorts 1-2) on day 0","label":"Cohort 3","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2038-12-08","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":23,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"CART-PSMA-TGFβRDN cells","otherNames":[],"type":"BIOLOGICAL"},{"name":"Cyclophosphamide","otherNames":[],"type":"DRUG"},{"name":"Fludarabine","otherNames":[],"type":"DRUG"}],"last_update":"2026-02-23","lead_sponsor":"University of Pennsylvania","official_title":"Phase I Study of CART-PSMA-TGFβRDN Cells in Patients With Advanced Castrate Resistant Prostate Cancer","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2038-09-08","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Occurrence of study related adverse events, laboratory toxicities and clinical events that are possibly, likely, or definitely related to study participation.","timeFrame":"15 years"},{"measure":"Clinical feasibility is defined as the frequency of subjects enrolled on this protocol who do not receive CART-PSMA-TGFβRDN cells.","timeFrame":"30 days"},{"measure":"Manufacturing feasibility is determined by the frequency of product release failures and the occurrence of dose failures (inability to meet target dose).","timeFrame":"30 days"}],"references":[{"citation":"Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, Farwell MD, Marshall A, Gilmore J, Lledo L, Dengel K, Church SE, Hether TD, Xu J, Gohil M, Buckingham TH, Yee SS, Gonzalez VE, Kulikovskaya I, Chen F, Tian L, Tien K, Gladney W, Nobles CL, Raymond HE; Prostate Cancer Cellular Therapy Program Investigators; Hexner EO, Siegel DL, Bushman FD, June CH, Fraietta JA, Haas NB. PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022 Apr;28(4):724-734. doi: 10.1038/s41591-022-01726-1. Epub 2022 Mar 21.","pmid":"35314843","type":"DERIVED"},{"citation":"Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH. Dominant-Negative TGF-beta Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Mol Ther. 2018 Jul 5;26(7):1855-1866. doi: 10.1016/j.ymthe.2018.05.003. Epub 2018 May 8.","pmid":"29807781","type":"DERIVED"}],"start_date":{"date":"2017-03-08","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer","url":"https://clinicaltrials.gov/study/NCT03089203"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03089203"}